Trial · NCT04439214

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

NCT04439214, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2021-04-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D). Trials, record NCT04439214. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04439214

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)
NCT number: NCT04439214
Status: Completed
Phases: Phase 2
Enrollment: 47 participants, actual
Lead sponsor: National Cancer Institute (NCI)
Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Plasma Cell Myeloma
Interventions: Nivolumab
First posted: 2020-06-19
Last updated: 2021-04-06
Results first posted: 2021-04-06

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Overall Response Rate (ORR)	assessed at baseline, then every 8 weeks for the first 2 years, then every 12 weeks in year 3, until disease progression	Overall response rate was defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) among all eligible and treated patients. Best overall response was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. The 90% two-sided binomial exact confidence interval was calculated for ORR.
Secondary	6-month Progression-free Survival (PFS) Rate	assessed at baseline, then every 8 weeks for the first 2 years, then every 12 weeks in year 3, until disease progression	PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. The 6-month PFS rate was estimated using the Kaplan-Meier method which can provide a point estimate for any specific time point. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients.
Secondary	Progression-free Survival (PFS)	assessed at baseline, then every 8 weeks for the first 2 years, then every 12 weeks in year 3, until disease progression	PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Overall Response Rate (ORR)	assessed at baseline, then every 8 weeks for the first 2 years, then every 12 weeks in year 3, until disease progression	Eligible and treated patients	percentage of participants	NUMBER
SECONDARY	6-month Progression-free Survival (PFS) Rate	assessed at baseline, then every 8 weeks for the first 2 years, then every 12 weeks in year 3, until disease progression	Eligible and treated patients	percentage of participants	NUMBER
SECONDARY	Progression-free Survival (PFS)	assessed at baseline, then every 8 weeks for the first 2 years, then every 12 weeks in year 3, until disease progression	Eligible and treated patients	months	MEDIAN

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Overall Response Rate (ORR)	Treatment (Nivolumab)	35.7	90% Confidence Interval 23.5 to 49.5	percentage of participants
6-month Progression-free Survival (PFS) Rate	Treatment (Nivolumab)	51.3	90% Confidence Interval 38.2 to 64.5	percentage of participants
Progression-free Survival (PFS)	Treatment (Nivolumab)	6.3	90% Confidence Interval 3.4 to 13.3	months

Source ClinicalTrials.gov

Participant flow7

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Treatment (Nivolumab)	47
Overall Study	Eligible	Treatment (Nivolumab)	42
Overall Study	Treated	Treatment (Nivolumab)	47
Overall Study	Treated and Reported Adverse Event Data	Treatment (Nivolumab)	46
Overall Study	Eligible and Treated	Treatment (Nivolumab)	42
Overall Study	COMPLETED	Treatment (Nivolumab)	0
Overall Study	NOT COMPLETED	Treatment (Nivolumab)	47

Source ClinicalTrials.gov

Adverse events61

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anemia	Blood and lymphatic system disorders	Treatment (Nivolumab)	12	46
other	Edema limbs	General disorders	Treatment (Nivolumab)	3	46
other	Fatigue	General disorders	Treatment (Nivolumab)	21	46
other	Pruritus	Skin and subcutaneous tissue disorders	Treatment (Nivolumab)	7	46
other	Rash maculo-papular	Skin and subcutaneous tissue disorders	Treatment (Nivolumab)	8	46
other	Hyperthyroidism	Endocrine disorders	Treatment (Nivolumab)	7	46
other	Hypothyroidism	Endocrine disorders	Treatment (Nivolumab)	7	46
other	Diarrhea	Gastrointestinal disorders	Treatment (Nivolumab)	6	46
other	Nausea	Gastrointestinal disorders	Treatment (Nivolumab)	6	46
other	Alanine aminotransferase increased	Investigations	Treatment (Nivolumab)	3	46

1 to 10 of 61Source ClinicalTrials.gov

See all 61 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Treatment (Nivolumab)	24	47
Total, other adverse events	Treatment (Nivolumab)	40	46
Total, serious adverse events	Treatment (Nivolumab)	20	46

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
31765263	RESULT

Source PubMed

Grants2

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years	Source
U10CA180820	ECOG-ACRIN Network Group Operations Center	ODwyer, Peter J; SCHNALL, MITCHELL D.	ECOG-ACRIN MEDICAL RESEARCH FOUNDATION	NATIONAL CANCER INSTITUTE	2014 to 2026	NIH RePORTER
U24CA196172	ECOG-ACRIN Biospecimen Bank to Support NCTN	JEWELL, SCOTT D; HAMILTON, STANLEY R.	ECOG-ACRIN MEDICAL RESEARCH FOUNDATION	NATIONAL CANCER INSTITUTE	2015 to 2025	NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04439214

GET https://conductscience.org/api/trials/v1/NCT04439214/events?page=2

API reference For AI assistants